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Abstract
FDA has recently asserted that many autologous cell therapies once considered the practice of medicine are in
fact drugs. These changes began with the creation of new sections of 21 CFR 1271 and a subsequent one word
change where the FDA, without public commentary, altered a single word in its regulatory language regarding cell
and tissue based therapies that asserted the authority to classify autologous tissue as drugs. The bright line
between medical care and drug production can be delineated in many ways, but a simple metric that defines the
dichotomy is the consent status of the patient. In healthcare, a patient can either be consented individually for a
medical procedure or exposed to an unconsented risk where regulatory assurances are already in place. These new
FDA policies apply rules meant to keep drugs safe in a drug factory (unconsented mass production risks) to
individually consented surgical procedures. We argue that there is little societal benefit to these changes and that
they are already stifling medical innovation.
Background
A recent editorial entitled, The King is Dead, Long Live
the King: Entering A New Era of Stem Cell Research
and Clinical Development by Ichim piqued our interest
[1]. The piece described how the recent failure by
Geron to commercialize embryonic stem cells for treat-
ment of spinal cord injury might have signaled the
decline of the commercial pursuit of such cells, and a
change of market focus from embryonic to adult stem
cells. We would argue that the primary reason that the
cell therapy industry now finds itself in the midst of a
financial funding crisis is in fact, due to unrestrained
over-regulation by the FDA, rather than any lack of via-
bility of the technologies. This over-regulation threatens
to smother innovation in a nascent clinical movement
that is already successfully translating promising thera-
pies involving adult stem cells from the lab to the clinic.
Although the FDA has never had the authority to gov-
ern and restrict the practice of medicine, this is precisely
what they are now doing with regard to clinical uses of
autologous stem cells. Until recently, this regulatory
expansion has gone largely unnoticed, attracting little
attention, with a few notable exceptions. To carry
Ichim’s regal metaphor a bit further, not only is the
king dead, but the emperor has no clothes, and nobody’s
telling him he’s naked.
Discussion
Since it was first enacted in 1938, the U.S. Food, Drug,
and Cosmetic Act (FDCA) has regulated medical drugs
and devices based on basic public health concepts that
recognize the differences between the practice of medi-
cine and the mass production of drugs [2]. The regula-
tion of mass manufactured and widely distributed
medical products led to a revolution in healthcare that
greatly increased public safety and unquestionably saved
lives due to the reduction of unsafe products. The FDA
regulation of transplant tissues through the Public
Health Service Act has also advanced the public health
through reduced disease transmission. This all changed
in 2006, when the FDA, without public commentary,
altered a single word in its regulatory language regard-
ing cell and tissue based therapies that moved their
focus from protecting the public from communicable
disease transmission to asserting authority over virtually
all therapies using autologous cells and tissue [3]. In
effect, the Agency now claims regulatory authority over
a broad category of medical procedures. Fifteen years * Correspondence: forensictrauma@gmail.com
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tsunami of objections and complaints; today, there is
nary a whimper [4].
The bright line between medical care and drug pro-
duction can be delineated in many ways, but a simple
metric that defines the dichotomy is the consent status
of the patient. In healthcare, a patient can either be con-
sented individually for a medical procedure or exposed
to an unconsented risk where regulatory assurances are
already in place. For example, an Individual Consented
Risk (ICR) is defined as a medical procedure or therapy
for which a patient is formally consented in order to
ensure a thorough understanding of the risks and possi-
ble benefits of the care. An example of ICR is a cardiac
surgery for which the health risk may be extreme and
the benefits difficult to quantify. In this situation the
onus is on the patient to make an informed decision,
after full disclosure of the best estimate of risk of the
procedure by the physician, whether to undergo the pro-
cedure. In contrast with ICR, Mass Production Risk
(MPR) is not associated with formal patient consent, as
there is a general assumption on the part of the pre-
scribing physician as well as the patient that the risk
associated with the use of medicine that has passed
through regulatory oversight is acceptably low. In the U.
S. the FDA is the entity that provides public assurance
that certain minimal standards (i.e. purity, potency, effi-
cacy, and safety) have been met before a drug can be
legally introduced to the market.
Cellular medicine is a rapidly growing trend in health-
care that finds itself at the confusing crossroads of the
regulatory concepts associated with ICR and MPR. An
example of a widespread practice of cellular medicine is
the use of autologous platelet rich plasma (PRP) to pro-
mote healing [5-7]. A less practiced but promising evo-
lution of PRP involves the use of adult autologous stem
cells (A-ASCs) for promotion of healing of injured tissue
[8]. From a common sense perspective, it should be
obvious that both of these autologous therapies are
associated with ICR rather MPR, in that there is no
mass production or distribution involved, the risk of
procedure to the individual patient can only be esti-
mated by the clinician who is providing the therapy, and
it is up to the patient to weigh and ultimately accept the
risk and provide consent for undergoing the procedure.
This sort of common sense is absent in the FDA’s adop-
tion of 21 CFR 1271 in 2006, the rule that made a
patient’s own cells subject to the same regulation as
mass produced drugs.
This movement away from common sense began in
the 1990’s when the FDA first signaled an interest in
regulating the use of autologous cells [4,9-11]. The
administrative records of the hearings from this time
show that many large and highly credible organizations
spoke out in opposition to this proposed intrusion into
the practice of medicine. The list of organizations that
objected to the FDA’sp r o p o s e dr u l ec h a n g ei n c l u d e d
the American Red Cross, the American Society for Clin-
ical Oncology, and the Society for Assisted Reproductive
T e c h n i q u e s ,a m o n go t h e r s .M a n yo ft h eg r o u p sn o t e d
that the FDA was only granted authority by the U.S.
Congress to regulate allogeneic tissue transplants in
order to control communicable disease transmission,
and that the Agency had no authority to regulate
human cells of any type like mass produced prescription
drugs. The most vocal opponent to these proposed reg-
ulations was the ASCO, who stated:
￿ “ASCO objects in the strongest terms to FDA’sp r o -
posed regulation of stem cell transplants. This misguided
proposal is unnecessary... and exceeds FDA’s legal
authority.
￿ “...stem cell transplants are medical procedures. Their
use is the practice of medicine, not the manufacturing of
a drug as FDA asserts.
￿ “A striking aspect of FDA’s proposal to regulate stem
cell procedures is the virtual absence of any justification
for the initiative”.
￿ “The FDA should not regulate stem cell procedures
undertaken within an institution... or in any other setting
where the cells are procured from a donor for a prese-
lected recipient under the direction of physicians caring
for these patients.... The proposed approach is a threat to
good medicine and should not be adopted.”
Despite these industry concerns, by 2005 the Agency
had completed publically announced changes to its reg-
ulations that classified “more than minimally manipu-
lated” allogeneic cells the same as prescription drugs.
This regulatory change at least made some sense, since
allogeneic cells could be grown in large bioreactors and
distributed to the public like a mass produced drug pro-
duct. The FDA did not stop at allogeneic cell therapy in
their bid to control all cellular therapy; in 2006, the
FDA “clarified” 1271, asserting that the rule applied to
all human tissue and cells, which meant that it now
applied to autologous cells and tissue as well. This was
accomplished with the alteration of a single word: “into
another human” was changed to “into a human.”
a For
the first time, by nothing more than semantic sleight of
hand, the agency bequeathed itself authority over a
broad group of medical procedures and their attendant
ICR risks. Recent decisions by agency show that it isn’t
yet done with expanding its regulatory authority into
the practice of medicine.
Since 2006 the FDA has made several public state-
ments regarding their intent to regulate the autologous
use of human cells and tissue, with an ever-widening
number of therapies being caught in their regulatory
dragnet. As an example, in 2008, the FDA sent a notice
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expanded bone marrow derived mesenchymal stem cells
for autologous orthopedic use [12]. Despite the medical
procedures involving only ICR, the FDA asserted that
their drug mass production rules applied to the prac-
tices at the clinic. In fact, the Agency’s actions directed
at Regenerative Sciences appear to only be the FDA’s
foot in the door of medical practice regulation, as long
as the practice involves use of autologous tissue or cells.
As an example, the Agency has recently made a worri-
some assertion about the processing of adipose tissue, a
medical practice that has been around for more than
100 years [13]. The Agency’s Tissue Reference Group
(TRG) has issued a statement in which they claim that
any isolation of the stem cell rich fraction of fatty tissue
for orthopedic use (the stromal vascular fraction or
SVF) by a physician for his or her own use in patients
equates to the manufacture of a drug, even if that tissue
is processed at the bedside [14]. In addition, the same
TRG has also recently issued the same edict for the use
of bedside processed SVF for breast reconstruction,
claiming this procedure is also a drug [15]. While the
same FDA arguments are used in this letter, more wor-
risome is that the agency claims that adipose stem cells
t a k e nf r o ma d i p o s et i s s u ea n du s e dt or e c o n s t r u c ta d i -
pose breast tissue may be non-homologous. Since the
agency’s own definition of homologous is, “[cells that]
perform the same basic function or functions”,i t ’s
unknown what logic drove this decision [16]. These
assertions will immediately restrict the medical practices
of hundreds of U.S. physicians who use SVF to assist in
healing, as no clinical practices can meet the stringent
regulations that are applied to drug manufacturing. In
addition, these decisions will only hamper medical inno-
vation without measurably improving public safety.
To illustrate how poorly thought out the language in
1271 is, consider a recent publication in which it was
reported that the magnetic field fluctuations of a routine
MRI changes the biologic characteristics of stem cells
[17]. These authors demonstrated that the magnetic
fields induced by diagnostic MRI can alter fundamental
biologic characteristics of stem cells such as gene
expression and bone forming ability. Thus if, as is com-
mon surgical practice, an orthopedic surgeon creates a
dilute autologous stem cell mix using a bone marrow
aspirate, places the mixture into a patient’s spine to pro-
mote fusion, and then orders an MRI post-procedure,
the stem cells will become more than minimally
manipulated. Whatever the FDA intended when they
slipped new and greatly expansive language into 21 CFR
1271 in 2006, it is doubtful that they intended to shut
down or restrict many commonly practiced and effective
medical therapies that have nothing to do the mass
manufacture and interstate of transport of drugs. It is
even more doubtful that the U.S. Congress ever
intended to the FDA to have such broad power over the
practice of medicine.
Should there be concern that the FDA will continue to
expand their attempts to regulate the practice of medi-
cine? The FDA has recently demonstrated that the
answer to this question is an emphatic YES. The afore-
mentioned action against Regenerative Sciences spawned
a series of suits and countersuits that are still in litiga-
tion. As part of this process, the Court hearing the cases
recently issued an “Order to Show Cause” to the FDA.
The order stated that, since Congress had only author-
ized the FDA to classify a substance that affected the
body through “chemical action” as a drug, the Agency
needed to clarify its position as to why a patient’so w n
stem cells could be considered a drug [18]. The
Agency’s response to the order was dismaying; they
responded with: “When living cells interact with their
environment to mediate repair of and/or regenerate
damaged tissue, they do so by chemical action.” Since all
living cells produce chemicals to interact with their
environment, the Agency has made it clear that they
believe that they have the authority to classify any living
organism as a drug!
Is it reasonable for the FDA to assert that there is any
benefit to imposing MPR regulations on medical proce-
dures involving ICR? Medical therapeutic innovation
comes to the public via two pathways; the slower big
pharma drug pathway, and the substantially faster physi-
cian practice/discovery pathway. The pharma pathway
has the advantage of producing high quality data from
randomized controlled trials in support of a new ther-
apy, but the disadvantages of inflexibility and glacially
slow laboratory to clinical translation. In comparison,
the physician practice pathway has the disadvantage of
reliance on lower quality data (beginning, in all cases,
with anecdotal experience), but the advantages of flex-
ibility and a shorter time from discovery to clinical
implementation. Physicians typically publish smaller stu-
dies that are reactive to problems encountered in daily
clinical practice, and result from the rapid adoption of
new therapies that appear to be effective in a semi- or
uncontrolled setting. The pharma pathway has the
potential to produce societal benefit in the form of
increasingly effective and safer prescription drugs, but it
is a far from foolproof system associated with a laundry
list of unsafe drugs that were initially hailed as medical
marvels (Vioxx, fen/phen, propoxyphene, Avandia, Bay-
col, inter alia) but later found to have unacceptable
rates of serious, sometimes fatal complications. The phy-
sician pathway has also produced major medical
advancements and benefits to public health such as
modern in-vitro fertilization and almost all modern sur-
gical procedures. To be sure, there have been major
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lobotomies, hysterectomies, and radical colectomies, to
name just a few), but the medical profession and the
bodies that provide education, licensure, regulation, and
peer review tend to rapidly self-correct for harmful
practices. The imposition of regulations meant to mini-
mize MPR on the pharma pathway makes sense, as this
pathway results in products meant for mass distribution.
In contrast, the attempt to shoehorn medical practices
into an MPR regulation model, as the FDA has done
with autologous stem cell therapies, will produce no
benefit to society, and harm public health by depriving
society of the benefits of physician-initiated medical
innovation.
Ultimately, the FDA’s assertion that certain clinical or
laboratory processes transform autologous cells into
drugs is not based in a scientific risk analysis, and goes
far beyond the Agency’s mandate to protect the public
from the risks associated with the mass production of
drugs or devices. It certainly begs the question of how
far the “medical procedure vs. drug” line may get rede-
fined in the future. Are there compounded drugs that
will be assigned MPR status? What about fertility cul-
ture procedures, such as a 5-day blastocyst transfer? If
the therapeutic culture of a human being from two
gametes isn’t “more than minimal manipulation” of
those cells then it’s hard to imagine what is. Will surgi-
cal procedures have to someday comply with drug man-
ufacturing guidelines?
All of these regulatory decisions have significant eco-
nomic consequences for society. For example, medical
care and drugs have different requirements for safety.
An apt example that demonstrates the societal cost
associated with imposing MPR regulations on ICR is
applying drug factory Good Manufacturing Practices
(GMP) to a hospital surgical procedure. GMP regula-
tions are strict guidelines that ensure a minimum level
of safety when millions of doses of a drug are manufac-
tured, but are not used in a hospital setting. For exam-
ple, if GMP regulations were applied to a hospital
setting they would require that a hospital operating
room (O.R) have a separate quality assurance program
as does a major pharmaceutical factory. All surgical sup-
plies would need to be separately validated to confirm
the already FDA regulated manufacturer’s claims. For
example, sterile medical gases already regulated by the
state would have to be again tested by the hospital. In
addition, every surface in the operating room would
have to be swabbed for microbial, viral, and fungal con-
tamination on a regular basis and the FDA regulated
cleaning solution claims separately validated in expen-
sive testing performed by the hospital staff. In addition,
each patient’sw o u n dw o u l da l s oh a v et ob es w a b b e d
and sent for microbial, viral, and fungal contaminants
before completion of the surgery. Operating room air
handling would also have to be upgraded to GMP stan-
dards, costing hundreds of thousands of dollars per O.R.
In addition, while surgeons are used to making adjust-
ments in technique to fit the patient, each change in
process would require a separate Standard Operating
Procedure change control process. As a result, surgeons
would be unable to alter the procedure to fit the patient.
In addition, every step in the surgery would have time
limits that would be strictly monitored and recorded
and when any step exceeded timed parameters the sur-
g e o nw o u l db ew r i t t e nu pb yaq u a l i t ya s s u r a n c em a n -
ager as having exceeded “processing parameters”. While
all of these changes may make good sense to protect the
nation’s drug supply from contamination, they make lit-
tle sense when applied to an operating room and would
also financially hobble an already expensive medical care
system.
Conclusion
The FDA has a long and important history of safeguard-
ing the health of the U.S., but always in the context of
its mandate to regulate medical products that carry with
them risks associated with mass production. For the
most part, the Agency usually gets it right; however in
altering that single word of 21 CFR 1271, the FDA has
overstepped its mandate, and through over expansive
regulation is threatening to cripple medical innovation.
Their most recent interpretation of 21 CFR 1271 indi-
cates that the FDA is in need of a course correction. It’s
time that someone has the courage to tell the Emperor
about the problems with his new wardrobe.
Endnote
aThus, section 1271.3(d) now states that “[h]uman cells,
tissues, or cellular or tissue-based products (HCT/Ps)
means articles containing or consisting of human cells
or tissues that are intended for implantation, transplan-
tation, infusion, or transfer into ah u m a nrecipient.”
21C.F.R. § 1271.3(d) (April 1, 2006) (emphasis added).
See also, 21C.F.R. § 1271.3(d)(1) (April 1, 2010).
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